Herschel*-ATLAS: correlations between dust and gas in local submm-selected galaxies

We present an analysis of CO molecular gas tracers in a sample of 500 μ m-selected Herschel -ATLAS galaxies at z < 0 . 05 ( cz < 14990 km s − 1 ). Using 22 − 500 μ m photom- etry from WISE , IRAS and Herschel , with H i data from the literature, we investigate correlations between warm and cold dust, and tracers of the gas in different phases. The correlation between global CO(3–2) line fluxes and FIR–submm fl uxes weakens with increasing IR wavelength ( λ & 60 μ m), as a result of colder dust being less strongly associated with dense gas. Conversely, CO(2–1) and H i line fluxes both ap- pear to be better correlated with longer wavelengths, suggesting that cold dust is more strongly associated with diffuse atomic and molecular gas phases, co nsistent with it being at least partially heated by radiation from old stellar populations . The increased scatter at long wavelengths implies that sub-millimetre fluxes are a po orer tracer of SFR. Fluxes at 22 and 60 μ m are also better correlated with diffuse gas tracers than dense CO(3–2), probably due to very-small-grain emission in the diffu se interstellar medium, which is not correlated with SFR. The FIR/CO luminosity ratio a nd the dust mass/CO luminosity ratio both decrease with increasing luminosit y, as a result of either correlations between mass and metallicity (changing CO/H 2 ) or between CO luminosity and excitation [changing CO(3–2)/CO(1–0)].Web of Scienc

Galaxy And Mass Assembly (GAMA): the galaxy stellar mass function to z = 0.1 from the r-band selected equatorial regions

We derive the low-redshift galaxy stellar mass function (GSMF), inclusive of dust corrections, for the equatorial Galaxy And Mass Assembly (GAMA) data set covering 180 deg2. We construct the mass function using a density-corrected maximum volume method, using masses corrected for the impact of optically thick and thin dust. We explore the galactic bivariate brightness plane (M⋆–μ), demonstrating that surface brightness effects do not systematically bias our mass function measurement above 107.5 M⊙. The galaxy distribution in the M–μ plane appears well bounded, indicating that no substantial population of massive but diffuse or highly compact galaxies are systematically missed due to the GAMA selection criteria. The GSMF is fitted with a double Schechter function, with M⋆=1010.78±0.01±0.20M⊙ M⋆=1010.78±0.01±0.20M⊙ , ϕ⋆1=(2.93±0.40)×10−3h370 ϕ1⋆=(2.93±0.40)×10−3h703 Mpc−3, α1 = −0.62 ± 0.03 ± 0.15, ϕ⋆2=(0.63±0.10)×10−3h370 ϕ2⋆=(0.63±0.10)×10−3h703 Mpc−3 and α2 = −1.50 ± 0.01 ± 0.15. We find the equivalent faint end slope as previously estimated using the GAMA-I sample, although we find a higher value of M⋆ M⋆ . Using the full GAMA-II sample, we are able to fit the mass function to masses as low as 107.5  M⊙, and assess limits to 106.5  M⊙. Combining GAMA-II with data from G10-COSMOS, we are able to comment qualitatively on the shape of the GSMF down to masses as low as 106 M⊙. Beyond the well-known upturn seen in the GSMF at 109.5, the distribution appears to maintain a single power-law slope from 109 to 106.5. We calculate the stellar mass density parameter given our best-estimate GSMF, finding Ω⋆=1.66+0.24−0.23±0.97h−170×10−3 Ω⋆=1.66−0.23+0.24±0.97h70−1×10−3 , inclusive of random and systematic uncertainties

Epstein-Barr virus: clinical and epidemiological revisits and genetic basis of oncogenesis

Epstein-Barr virus (EBV) is classified as a member in the order herpesvirales, family herpesviridae, subfamily gammaherpesvirinae and the genus lymphocytovirus. The virus is an exclusively human pathogen and thus also termed as human herpesvirus 4 (HHV4). It was the first oncogenic virus recognized and has been incriminated in the causation of tumors of both lymphatic and epithelial nature. It was reported in some previous studies that 95% of the population worldwide are serologically positive to the virus. Clinically, EBV primary infection is almost silent, persisting as a life-long asymptomatic latent infection in B cells although it may be responsible for a transient clinical syndrome called infectious mononucleosis. Following reactivation of the virus from latency due to immunocompromised status, EBV was found to be associated with several tumors. EBV linked to oncogenesis as detected in lymphoid tumors such as Burkitt's lymphoma (BL), Hodgkin's disease (HD), post-transplant lymphoproliferative disorders (PTLD) and T-cell lymphomas (e.g. Peripheral T-cell lymphomas; PTCL and Anaplastic large cell lymphomas; ALCL). It is also linked to epithelial tumors such as nasopharyngeal carcinoma (NPC), gastric carcinomas and oral hairy leukoplakia (OHL). In vitro, EBV many studies have demonstrated its ability to transform B cells into lymphoblastoid cell lines (LCLs). Despite these malignancies showing different clinical and epidemiological patterns when studied, genetic studies have suggested that these EBV- associated transformations were characterized generally by low level of virus gene expression with only the latent virus proteins (LVPs) upregulated in both tumors and LCLs. In this review, we summarize some clinical and epidemiological features of EBV- associated tumors. We also discuss how EBV latent genes may lead to oncogenesis in the different clinical malignancie

Herschel -ATLAS: rapid evolution of dust in galaxies over the last 5 billion years

We present the first direct and unbiased measurement of the evolution of the dust mass function of galaxies over the past 5 billion years of cosmic history using data from the Science Demonstration Phase of the Herschel-Astrophysical Terahertz Large Area Survey (Herschel-ATLAS). The sample consists of galaxies selected at 250 ?m which have reliable counterparts from the Sloan Digital Sky Survey (SDSS) at z < 0.5, and contains 1867 sources. Dust masses are calculated using both a single-temperature grey-body model for the spectral energy distribution and also a model with multiple temperature components. The dust temperature for either model shows no trend with redshift. Splitting the sample into bins of redshift reveals a strong evolution in the dust properties of the most massive galaxies. At z= 0.4-0.5, massive galaxies had dust masses about five times larger than in the local Universe. At the same time, the dust-to-stellar mass ratio was about three to four times larger, and the optical depth derived from fitting the UV-sub-mm data with an energy balance model was also higher. This increase in the dust content of massive galaxies at high redshift is difficult to explain using standard dust evolution models and requires a rapid gas consumption time-scale together with either a more top-heavy initial mass function (IMF), efficient mantle growth, less dust destruction or combinations of all three. This evolution in dust mass is likely to be associated with a change in overall interstellar medium mass, and points to an enhanced supply of fuel for star formation at earlier cosmic epochs

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

Background: Sleep disturbance is common following hospital admission both for COVID-19 and other causes. The clinical associations of this for recovery after hospital admission are poorly understood despite sleep disturbance contributing to morbidity in other scenarios. We aimed to investigate the prevalence and nature of sleep disturbance after discharge following hospital admission for COVID-19 and to assess whether this was associated with dyspnoea. Methods: CircCOVID was a prospective multicentre cohort substudy designed to investigate the effects of circadian disruption and sleep disturbance on recovery after COVID-19 in a cohort of participants aged 18 years or older, admitted to hospital for COVID-19 in the UK, and discharged between March, 2020, and October, 2021. Participants were recruited from the Post-hospitalisation COVID-19 study (PHOSP-COVID). Follow-up data were collected at two timepoints: an early time point 2–7 months after hospital discharge and a later time point 10–14 months after hospital discharge. Sleep quality was assessed subjectively using the Pittsburgh Sleep Quality Index questionnaire and a numerical rating scale. Sleep quality was also assessed with an accelerometer worn on the wrist (actigraphy) for 14 days. Participants were also clinically phenotyped, including assessment of symptoms (ie, anxiety [Generalised Anxiety Disorder 7-item scale questionnaire], muscle function [SARC-F questionnaire], dyspnoea [Dyspnoea-12 questionnaire] and measurement of lung function), at the early timepoint after discharge. Actigraphy results were also compared to a matched UK Biobank cohort (non-hospitalised individuals and recently hospitalised individuals). Multivariable linear regression was used to define associations of sleep disturbance with the primary outcome of breathlessness and the other clinical symptoms. PHOSP-COVID is registered on the ISRCTN Registry (ISRCTN10980107). Findings: 2320 of 2468 participants in the PHOSP-COVID study attended an early timepoint research visit a median of 5 months (IQR 4–6) following discharge from 83 hospitals in the UK. Data for sleep quality were assessed by subjective measures (the Pittsburgh Sleep Quality Index questionnaire and the numerical rating scale) for 638 participants at the early time point. Sleep quality was also assessed using device-based measures (actigraphy) a median of 7 months (IQR 5–8 months) after discharge from hospital for 729 participants. After discharge from hospital, the majority (396 [62%] of 638) of participants who had been admitted to hospital for COVID-19 reported poor sleep quality in response to the Pittsburgh Sleep Quality Index questionnaire. A comparable proportion (338 [53%] of 638) of participants felt their sleep quality had deteriorated following discharge after COVID-19 admission, as assessed by the numerical rating scale. Device-based measurements were compared to an age-matched, sex-matched, BMI-matched, and time from discharge-matched UK Biobank cohort who had recently been admitted to hospital. Compared to the recently hospitalised matched UK Biobank cohort, participants in our study slept on average 65 min (95% CI 59 to 71) longer, had a lower sleep regularity index (–19%; 95% CI –20 to –16), and a lower sleep efficiency (3·83 percentage points; 95% CI 3·40 to 4·26). Similar results were obtained when comparisons were made with the non-hospitalised UK Biobank cohort. Overall sleep quality (unadjusted effect estimate 3·94; 95% CI 2·78 to 5·10), deterioration in sleep quality following hospital admission (3·00; 1·82 to 4·28), and sleep regularity (4·38; 2·10 to 6·65) were associated with higher dyspnoea scores. Poor sleep quality, deterioration in sleep quality, and sleep regularity were also associated with impaired lung function, as assessed by forced vital capacity. Depending on the sleep metric, anxiety mediated 18–39% of the effect of sleep disturbance on dyspnoea, while muscle weakness mediated 27–41% of this effect. Interpretation: Sleep disturbance following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness. Due to the association with multiple symptoms, targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition. Funding: UK Research and Innovation, National Institute for Health Research, and Engineering and Physical Sciences Research Council

Collision probabilities for plate geometry cells with an approximate treatment of plate edge regions

Available from British Library Lending Division - LD:9091.9F(AEEW-R--1923) / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo